Double jeopardy: Lung cancer after cardiac transplantation

Chest

Volumn 113, Issue 6, 1998, Pages 1720-1723

  Johnson, William M ^a   Baldursson, Olafur ^a   Gross, Thomas J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Bronchogenic carcinoma; Heart transplant; Immunosuppression

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; PREDNISONE;

ADULT; ARTICLE; CANCER RISK; CASE REPORT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; LUNG CARCINOMA; MALE; PRIORITY JOURNAL; SMOKING; THORAX RADIOGRAPHY;

EID: 0031780301     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.6.1720     Document Type: Article

References (19)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics 1997. CA Cancer J Clin 1997; 47:5-27
2. Penn I. Depressed immunity and the development of cancer. Clin Exp Immunol 1981; 46:459-74
3. Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am 1993; 7:431-45
4. Pham SM, Kormos RL, Landreneau RJ, et al. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 1995; 60:1623-26
5. Goldstein DJ, Austin JH, Zuech N, et al. Carcinoma of the lung after heart transplantation. Transplantation 1996; 62: 772-75
6. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89:225S-233S
7. Tollerud DJ, Clark JW, Brown LM, et al. Association of cigarette smoking with decreased numbers of circulating natural killer cells. Am Rev Respir Dis 1989; 139: 194-98
8. Fleming RH, Jennison SH, Naunheim KS. Primary bronchogenic carcinoma in the heart transplant recipient. Ann Thorac Surg 1994; 57:1300-01
9. Penn I. Why do immunosuppressed patients develop cancer? Crit Rev Oncog 1989; 1:27-52
10. Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993; 12(suppl):S328-36
11. Olivari MT, Diekmann RA, Kubo SH, et al. Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression. J Heart Transplant 1990; 9:618-21
12. Kehinde EO, Petermann A, Morgan JD, et al. Triple therapy and incidence of de novo cancer in renal transplant recipients. Br J Surg 1994; 81:985-86
13. Montagnino G, Lorca E, Tarantino A, et al. Cancer incidence in 854 kidney transplant recipients from a single institution: comparison with normal population and with patients under dialytic treatment. Clin Transplant 1996; 10:461-69
14. Brunner FP, Landais P, Selwood NH. Malignancies after renal transplantation: the EDTA-ERA registry experience. Nephrol Dial Transplant 1995; 10(suppl 1):74-80
15. Barrett WL, First MR, Aron BS, et al. Clinical course of malignancies in renal transplant recipients. Cancer 1993; 72:2186-89
16. Chan TK, Aranda CP, Rom WN. Bronchogenic carcinoma in young patients at risk for acquired immunodeficiency syndrome. Chest 1993; 103:862-64
17. Karp J, Profeta G, Marantz PR, et al. Lung cancer in patients with immunodeficiency syndrome. Chest 1993; 103:410-13
18. Tenholder MF, Jackson HD. Bronchogenic carcinoma in patients seropositive for human immunodeficiency virus. Chest 1993; 104:1049-53
19. Khuri FR, Lippman SM, Spitz MR, et al. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997; 89:199-211